Payer insights for cell and gene therapies

It is essential to address the payer landscape very early in development for a product administered once with a lifelong effect, such as a gene therapy. The one-time, front-loaded costs of these treatments have necessitated new payment models to win payer approval and be affordable. In this short video, Emma Medin, VP, Pricing & Market Access, shares three payer insights to help you price appropriately for your cell or gene therapy. Get more insights from our experts by visiting https://www.parexel.com/neverstop.

Previous Article
Regulatory considerations from former FDA regulators
Regulatory considerations from former FDA regulators

In this infographic, we’ve compiled some common questions our ex-FDA experts get asked, along with their pe...

Next Flipbook
Dosing strategies for gene therapies
Dosing strategies for gene therapies

In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline ...

×

Let's start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!